Autopsy report · NCT01095445

EXtended Therapy in Hepatitis C Genotype 3 Infected Patients

“Unlikely to recruit the adequate number of patients within a reasonable timeline”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 1 year 4 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

University Health Network, Toronto

Sponsor type

University, hospital or other

Conditions

Chronic Hepatitis C

Interventions

Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)

Participants

2

Sites

12

Countries

Canada

Trials that died the same way

• Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
  “difficulties to recruit planned numbers of patients within reasonable time frame” (81% match in meaning)
• Propofol and Dexmedetomidin vs Midazolam Intraoperative Sedation and POCD
  “Too long recruitment period due to small number of patients” (75% match in meaning)
• Fesoterodine on Urgency Episodes in Parkinson's Disease Population
  “Insufficient or untimely patient recruitment” (74% match in meaning)
• TuLip : Role of the Tumor Environment in Cancer-related Fat Loss
  “Limited number of recruited patients” (74% match in meaning)
• Evaluation of the Parietex TM Parastomal No Hole Mesh for Repair of Parastomal Hernias in End-colostomies
  “too slow patiënts recruitment” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.